By Counterforce Health Team in Enhertu (fam-trastuzumab deruxtecan-nxki) —

Myths vs. Facts: Getting Enhertu (fam-trastuzumab deruxtecan-nxki) Covered by Cigna in Virginia

Answer Box: Getting Enhertu Covered by Cigna in Virginia

Myth: If your doctor prescribes Enhertu, Cigna automatically covers it. Fact: Cigna requires detailed prior authorization with HER2 biomarker testing documentation following CAP/ASCO guidelines. Virginia residents have strong appeal rights through the State Corporation Commission Bureau of Insurance external review process. First step: Gather HER2 pathology reports with IHC scores and FDA-approved assay documentation before submitting your prior authorization request.

Table of Contents

  1. Why Myths About Enhertu Coverage Persist
  2. Top Myths vs. Facts About Cigna Coverage
  3. What Actually Influences Approval
  4. Avoid These Common Mistakes
  5. Quick Action Plan: Three Steps to Take Today
  6. Virginia Resources and Appeals Process
  7. FAQ
  8. Sources & Further Reading

Why Myths About Enhertu Coverage Persist

Enhertu (fam-trastuzumab deruxtecan-nxki) represents cutting-edge cancer treatment, but myths about insurance coverage create unnecessary delays and denials. These misconceptions persist because:

  • Complex approval criteria that vary by tumor type and HER2 status
  • Rapidly evolving FDA approvals for new indications that insurers may not immediately recognize
  • High costs (approximately $2,440 per 100mg vial) that trigger intensive utilization management
  • Recent litigation against Cigna over automated denial algorithms affecting specialty oncology drugs

Understanding the facts helps patients and clinicians navigate Cigna's approval process more effectively in Virginia.

Top Myths vs. Facts About Cigna Coverage

Myth 1: "If my oncologist prescribes Enhertu, Cigna has to cover it"

Fact: Cigna requires comprehensive prior authorization regardless of physician recommendation. Coverage depends on meeting specific medical necessity criteria, proper HER2 biomarker documentation, and adherence to FDA-approved indications.

Myth 2: "Any HER2 test result is sufficient for approval"

Fact: Cigna and Express Scripts require detailed HER2 testing documentation that follows CAP/ASCO guidelines. The pathology report must include:

  • FDA-approved IHC and/or ISH assay methods
  • Specific antibody clones used
  • IHC scores (0-3+) and ISH results if IHC 2+
  • Specimen handling details and compliance statements

Myth 3: "Denials are final—there's no point in appealing"

Fact: Virginia has a robust external review process through the State Corporation Commission Bureau of Insurance. Patients have 120 days to request external review after Cigna's final denial. The independent review organization's decision is binding on the insurer.

Myth 4: "Step therapy doesn't apply to cancer drugs"

Fact: Cigna may require trying less expensive HER2-targeted therapies first, depending on your specific cancer type and treatment history. However, documented failures or contraindications to first-line therapies can override step therapy requirements.

Myth 5: "All cancer centers can administer Enhertu"

Fact: Cigna may restrict Enhertu to specific infusion centers or require pre-approval for site of care. The drug requires specialized monitoring for interstitial lung disease (ILD), with 9-12% incidence rates.

Myth 6: "Generic alternatives exist for Enhertu"

Fact: Enhertu is a unique antibody-drug conjugate with no generic equivalents. However, Cigna may require trying other HER2-targeted therapies like trastuzumab/pertuzumab combinations or T-DM1 before approving Enhertu.

Myth 7: "Prior authorization is just a formality"

Fact: Cigna uses sophisticated review processes, and recent investigations revealed automated denial systems that can reject claims in batches. Thorough documentation is essential for approval.

Myth 8: "Medicare patients have easier access than commercial insurance"

Fact: Cigna's commercial and Medicare Advantage plans may have different formulary tiers and prior authorization requirements. Medicare Part D coverage through Cigna follows similar medical necessity criteria but may have different appeal timelines.

What Actually Influences Approval

Medical Necessity Criteria

Cigna evaluates Enhertu requests based on:

Tumor-Specific Requirements:

  • HER2-positive breast cancer: Prior trastuzumab-based therapy
  • HER2-mutant NSCLC: Documented HER2 mutation via NGS or other validated testing
  • HER2-positive gastric/GEJ cancer: Prior HER2-targeted therapy failure

Documentation Standards:

  • Complete pathology reports with CAP/ASCO compliant HER2 testing
  • Prior therapy history with dates and outcomes
  • Performance status and life expectancy assessments
  • ILD risk mitigation plan with baseline chest imaging

Routing and Submission Process

Express Scripts Specialty Pharmacy typically manages Enhertu prior authorizations for Cigna members. Requests must include:

  • Completed prior authorization form
  • Clinical notes documenting diagnosis and prior treatments
  • HER2 testing reports
  • Baseline chest CT results
Tip: Submit requests through Cigna's provider portal rather than fax when possible to ensure faster processing and tracking.

Avoid These Common Mistakes

1. Incomplete HER2 Testing Documentation

Mistake: Submitting pathology reports without specific assay methods or CAP/ASCO compliance statements.

Fix: Ensure reports include FDA-approved assay details, antibody clones, and explicit compliance language. Contact the pathology lab if documentation is incomplete.

2. Missing Prior Therapy Details

Mistake: Vague statements like "failed prior HER2 therapy."

Fix: Document specific agents, dates, duration, and reasons for discontinuation (progression, toxicity, contraindication).

3. Inadequate ILD Risk Assessment

Mistake: Not addressing Enhertu's boxed warning for interstitial lung disease.

Fix: Include baseline chest imaging, patient counseling documentation, and monitoring plan for respiratory symptoms.

4. Wrong Site of Care Authorization

Mistake: Assuming any infusion center can administer Enhertu.

Fix: Verify Cigna's preferred infusion network and obtain site-specific authorization if required.

5. Missing Appeal Deadlines

Mistake: Waiting too long to file appeals or external review requests.

Fix: Virginia residents have 120 days from final denial to request external review. File promptly and consider expedited review for urgent cases.

Quick Action Plan: Three Steps to Take Today

Step 1: Gather Essential Documentation

Patient Action: Request copies of all HER2 testing reports from your pathology lab. Verify they include:

  • Assay methodology and antibody clones
  • IHC scores and ISH results (if applicable)
  • CAP/ASCO compliance statements

Clinician Action: Document complete prior therapy history with specific agents, dates, and outcomes. Order baseline chest CT if not already done.

Step 2: Submit Comprehensive Prior Authorization

Submit to: Express Scripts Specialty Pharmacy (verify current portal access) Include:

  • Completed PA form with all required fields
  • HER2 testing documentation
  • Prior therapy summary
  • ILD risk mitigation plan
  • Site of care authorization request

Step 3: Prepare for Potential Denial

Set up tracking: Monitor request status through Cigna member portal Gather appeal resources: Save Virginia Bureau of Insurance contact information (1-877-310-6560) Document timeline: Note submission dates for appeal deadline calculations

Virginia Resources and Appeals Process

State Corporation Commission Bureau of Insurance

Virginia residents have strong appeal rights through the external review process:

Contact Information:

Timeline:

  • 120 days from final denial to request external review
  • 45 days for standard review decision
  • 72 hours for expedited review (with physician certification)

Virginia Managed Care Ombudsman

The Office of the Managed Care Ombudsman provides patient advocacy services for managed care plan issues:

  • Phone: 1-877-310-6560
  • Services: Appeal guidance, informal dispute resolution, HMO issue assistance

Additional Support Resources

Virginia Department of Medical Assistance Services (for Medicaid appeals):

ENROLL Virginia (for marketplace issues):

Note: Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into targeted, evidence-backed appeals by analyzing denial letters and crafting point-by-point rebuttals aligned to plan policies.

FAQ

Q: How long does Cigna prior authorization take for Enhertu in Virginia? A: Standard prior authorization typically takes 5-15 business days. Expedited reviews for urgent cases may be completed in 24-72 hours with proper clinical justification.

Q: What if Enhertu is non-formulary on my Cigna plan? A: You can request a formulary exception through the prior authorization process. Include clinical rationale for why formulary alternatives are inappropriate or contraindicated.

Q: Can I request an expedited appeal if Cigna denies coverage? A: Yes, Virginia allows expedited external review within 72 hours if delay would jeopardize life, health, or maximum function. Requires physician certification.

Q: Does step therapy apply if I've failed HER2 therapies in another state? A: Yes, documented prior therapy failures from any location should satisfy step therapy requirements. Ensure complete documentation of previous treatments and outcomes.

Q: What happens if the external review overturns Cigna's denial? A: The decision is binding on Cigna. The insurer must provide coverage as determined by the independent review organization, typically within 1-3 days of the decision.

Q: Are there financial assistance programs for Enhertu? A: Yes, Daiichi Sankyo offers patient assistance programs. Contact their patient support services for eligibility requirements and application processes.

Counterforce Health specializes in helping patients navigate complex prior authorization processes and appeal insurance denials through evidence-based advocacy. Their platform analyzes denial letters and crafts targeted rebuttals using payer-specific workflows and clinical evidence.

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance plan for specific coverage decisions. For official Virginia insurance regulations and appeal procedures, contact the State Corporation Commission Bureau of Insurance.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.